Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...

The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

The biotech company said it anticipates between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...

Moderna Inc. entered the new year on the heels ... “(If I) tell you there’s this new biotech company…that has $2 billion of sales, two products approved, $9 billion in the bank, just filed ...

The S&P 500 ended 0.2% higher on Monday, Jan. 13, 2025, ahead of this week's inflation data and the first wave of earnings ...

In a report released today, Terence Flynn from Morgan Stanley assigned a Hold rating on Moderna (MRNA – Research Report), with a price target ...